| 发明名称 |
KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS |
| 摘要 |
The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma. |
| 申请公布号 |
US2016130346(A1) |
申请公布日期 |
2016.05.12 |
| 申请号 |
US201414892779 |
申请日期 |
2014.05.28 |
| 申请人 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ;ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ;UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE ;UNIVERSITE PARIS DIDEROT - PARIS 7 |
发明人 |
GAULARD Philippe;ORTONNE Nicolas;MARIE-CARDINE Anne;BENSUSSAN Armand |
| 分类号 |
C07K16/28;C07K16/30;C12N15/117;G01N33/574 |
主分类号 |
C07K16/28 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A ligand molecule, that specifically binds to KIR3DL2 for the prevention and/or the treatment of a KIR3DL2 expressing malignant T-cells lymphoma selected from the group comprising sub-cutaneous panniculitis-like T-cell lymphoma, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, enteropathy-associated T-cell lymphoma and hepatosplenic gamma-delta T-cell lymphoma. |
| 地址 |
Paris FR |
